The global cytotoxic drugs market is experiencing significant growth, driven by increasing cancer prevalence, rising awareness about targeted therapies, and advancements in oncology treatments. Cytotoxic drugs, which work by killing or inhibiting the growth of cancer cells, are primarily used in chemotherapy regimens for various types of cancers, including lung, breast, and colorectal cancer. The market is also being fueled by the growing demand for combination therapies, as cytotoxic drugs are often used in conjunction with other treatment modalities like immunotherapy and targeted therapy for enhanced therapeutic efficacy. In addition, the introduction of novel cytotoxic agents, such as antibody-drug conjugates (ADCs), has contributed to expanding treatment options for hard-to-treat cancers, further driving market growth. The increasing adoption of personalized medicine is another key factor, as it allows for more tailored treatment approaches, improving the efficacy and minimizing side effects of cytotoxic drugs.
